BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: CUB domain containing protein 1 (CDCP1); epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu)

May 28, 2015 7:00 AM UTC

Cell culture, mouse and patient sample studies suggest inhibiting CDCP1 could help treat Herceptin trastuzumab-resistant breast cancer. In HER2-positive primary and metastastic breast tumors from pati...